큐렉소

060280KOSDAQ기타 상품 전문 소매업

52.0 / 100

Reference Date: 2026-04-13

Financial Score15.5 / 40

News Sentiment18.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly down 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Quelex operates in three business segments: medical robotics, implants, and trade. It sells surgical robots such as 'Cuvis-Joint' and 'Cuvis-Spine' for orthopedic and spinal surgery, as well as a rehabilitation robot called 'Morning Walk'. The medical robotics market is growing rapidly due to increased demand for minimally invasive surgery, with the spinal surgery robot market projected to reach $2.77 billion by 2022.

Number of Employees

103people

Average Salary

62.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

219.40Industry Average 113.191.5Point

1.9x industry avg (risky)

PBR

6.30Industry Average 1.740.0Point

3.6x industry avg (risky)

ROE

2.92Industry Average 2.924.0Point

In line with industry avg

Debt Ratio

0.70Industry Average 10.138.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼236.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.8% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 0Average Sentiment Score 90

Positive
큐렉소 척추수술로봇 ‘큐비스-스파인’, 혁신의료기술 다기관 임상 ...
큐렉소의 척추 수술로봇 시스템 '큐비스-스파인'이 혁신의료기술 다기관 임상시험에 본격 진입하며 제도권 시장 안착에 속도를 내고 있습니다.
Positive
큐렉소, 인공관절 수술로봇 美 FDA 승인 획득 ... 미국 진출 본격...
큐렉소의 인공관절 수술 로봇 '큐비스-조인트'가 미국 FDA 승인을 획득하여 세계 최대 의료기기 시장인 미국 진출을 본격화할 수 있게 되었습니다.
Positive
큐렉소 인공관절수술로봇 큐비스-조인트, 美 FDA 승인
큐렉소가 인공관절수술로봇 '큐비스-조인트'의 미국 FDA 승인을 획득하며 19조 원 규모의 세계 최대 미국 인공관절 수술 시장을 조준하고 글로벌 실적 성장을 본격화할 것으로 기대됩니다.

Detailed Momentum

52-week position5.0Point

52w mid range (54%)

Current 14,700Won52-week high 20,35052-week low 7,970

1-month return2.0Point

1m -2.65% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-04-07
Neutral기타경영사항(자율공시) (미국 식품의약국(FDA) 인허가 'FDA 510(k) 클리어런스' 획득 )(CUVIS-joint,자동화시스템로봇수술기)2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-17
Neutral감사보고서제출2026-03-16